Home › Research › Treatments
Psychosis of Alzheimer disease: validity of the construct and response to risperidone
Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2003-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective The authors evaluated the efficacy of risperidone in reducing psychotic and aggressive symptoms in a subgroup of patients who fulfilled operationalized criteria for psychosis of dementia. Methods Authors conducted a subgroup analysis of patients in the risperidone database arising from a previous double-blind, randomized, placebo-controlled study. In the primary study, patients age 55 or older, with a DSM-IV diagnosis of Alzheimer disease and/or vascular dementia were randomized to placebo or 0.5 mg, 1.0 mg, or 2.0 mg/day of risperidone. For this analysis, patients were selected who fulfilled operationalized criteria for psychosis of dementia. These criteria were then validated. The primary outcome measures were the newly developed Psychosis and Aggression Severity Indices, derived from Parts 1 and 2 of the BEHAVE-AD rating scale. Results At Week 12 and endpoint, patients with psychosis of dementia receiving 1 mg or 2 mg/day of risperidone showed significantly more improvement on the Psychosis Severity and Aggressiveness Severity Indices than those receiving placebo. Conclusions The construct of psychosis of dementia was validated, and the severity of both psychosis and aggressiveness was reduced with risperidone treatment in a robust and dose-related way, with a continuing response over the 12-week trial period.
What this study adds
Evidence grade: High
This is a trial. In this subgroup analysis, risperidone at 1 mg or 2 mg per day reduced psychosis and aggressiveness symptoms compared with placebo in patients with psychosis of dementia. Reported effect size: or 0.5; or 2.0.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schneider, L. S., Katz, I. R., Park, S., Napolitano, J., Martinez, R. A., & Azen, S. P. (2003). Psychosis of Alzheimer disease: validity of the construct and response to risperidone. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. https://doi.org/10.1176/appi.ajgp.11.4.414
Vancouver
Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2003. doi:10.1176/appi.ajgp.11.4.414. PMID: 12837670.
BibTeX
@article{schneider2003-12837670,
author = {Schneider, L. S. and Katz, I. R. and Park, S. and Napolitano, J. and Martinez, R. A. and Azen, S. P.},
title = {{Psychosis of Alzheimer disease: validity of the construct and response to risperidone}},
journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
year = {2003},
doi = {10.1176/appi.ajgp.11.4.414},
pmid = {12837670},
url = {https://doi.org/10.1176/appi.ajgp.11.4.414}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results At Week 12 and endpoint, patients with psychosis of dementia receiving 1 mg or 2 mg/day of risperidone showed significantly more improvement on the Psychosis Severity and Aggressiveness Severity Indices than those receiving placebo.
Why it matters
In this subgroup analysis, risperidone at 1 mg or 2 mg per day reduced psychosis and aggressiveness symptoms compared with placebo in patients with psychosis of dementia. This concerns treating behavioral symptoms of Alzheimer's disease, not curing or preventing it.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect sizeor 0.5; or 2.0
- Evidence strengthHigh
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design and sample size because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 40 of the 96 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.4 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 1 / 6 | Cited 1.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Lon S. S. Schneider: h-index 87 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12837670) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 40 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 96 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.